ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO1104

The Association of the Influenza Vaccination with CKD Progression to ESKD in a High-Risk Patient Population

Session Information

Category: CKD (Non-Dialysis)

  • 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Wilson, Clara, Montefiore Medical Center, Bronx, New York, United States
  • Li, Jun, Montefiore Medical Center, Bronx, New York, United States
  • Jobson, Crystal K., Montefiore Medical Center, Bronx, New York, United States
  • Fisher, Molly, Montefiore Medical Center, Bronx, New York, United States
  • Johns, Tanya S., Montefiore Medical Center, Bronx, New York, United States
  • Melamed, Michal L., Montefiore Medical Center, Bronx, New York, United States
Background

Individuals with CKD who received influenza vaccination have lower risk of infection-related hospitalizations, cardiovascular events, and mortality compared to unvaccinated. However, the association between influenza vaccination status and risk of progression to ESKD has not been studied.

Methods

We describe a cohort of 4,020 adult patients with CKD stage 3b or 4 (eGFR < 45 mL/min/1.73 m2) identified through ATLAS and FluSurv-Net database from 9/2008 to 9/2010 (index dates) at risk for progression to ESKD. Primary exposure was receipt of influenza vaccine during the index period. Patient were followed to ESKD (primary outcome) or administratively censored at 12/31/2019. Multivariable Cox proportional hazards models were used to determine the association between influenza vaccination status and progression to ESKD.

Results

In this cohort, 46% were unvaccinated and 54% vaccinated. Vaccinated patients mean age was 71 years (SD 13.2), were predominantly Black (45.7%) and Hispanic (27.5%). Compared to unvaccinated patients, vaccinated patients were significantly older, more likely to be female, White or Hispanic, have higher baseline eGFR and comorbidities like hypertension, diabetes, congestive heart failure, peripheral vascular disease, malignancy, and neurologic disease (Table 1). In the unadjusted Cox model, risk of progression to ESKD in unvaccinated vs. vaccinated patients was 24% higher [HR 0.76 (95% CI: 0.67, 0.86)]. However, this risk attenuated [HR 0.92 (95% CI 0.81, 1.03)] after adjusting for age, sex, race/ethnicity, and comorbidities.

Conclusion

Influenza vaccination was associated with a lower risk of progression from CKD to ESKD; however, significance of risk reduction was attenuated by concomitant comorbidities and sociodemographic factors.